LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListAlkermes PLC

Alkermes PLC

Closed

24.97 -4.55

Overview

Share price change

24h

Current

Min

24.9

Max

26.17

Key metrics

By Trading Economics

Income

-189M

48M

Sales

-3.5M

377M

P/E

Sector Avg

49.468

23.904

EPS

0.22

Profit margin

12.537

EBITDA

-190M

69M

Recommendations

By TipRanks

Rating Consensus

Buy

12 Months Forecast

+43.06 upside

Dividends

By Dow Jones

Next earnings

24 Apr 2024

Market Stats

By TradingEconomics

Market Cap

-24M

4.4B

Previous open

29.52

Previous close

24.97

Technical Score

By Trading Central

Confidence

Neutral Evidence

Alkermes PLC chart

Related News

14 Dec 2023, 11:06 UTC

Acquisitions, Mergers, TakeOvers

Alkermes Athlone Facility Has About 400 Employees >ALKS

14 Dec 2023, 11:06 UTC

Acquisitions, Mergers, TakeOvers

Alkermes to Get Cash Payment of $92.5 Million for Facility, Related Assets >ALKS

Peer Comparison

Price change

Alkermes PLC forecast

Price Target

By TipRanks

43.06% upside

12 Months Forecast

Average 35.75 USD  43.06%

High 50 USD

Low 25 USD

Based on 11 Wall Street analysts offering 12 month price targets for Alkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

5

Buy

5

Hold

1

Sell

Technical Score

By Trading Central

N/A / 26.385 Support&Resistance

Short Team

Neutral Evidence

Intermediate Term

Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.